| Literature DB >> 27113598 |
Yan Zhao1, Jorik Nonnekes2,3, Erik J M Storcken2, Sabine Janssen2,4, Erwin E H van Wegen5, Bastiaan R Bloem4, Lucille D A Dorresteijn6, Jeroen P P van Vugt6, Tjitske Heida2, Richard J A van Wezel2,7.
Abstract
New mobile technologies like smartglasses can deliver external cues that may improve gait in people with Parkinson's disease in their natural environment. However, the potential of these devices must first be assessed in controlled experiments. Therefore, we evaluated rhythmic visual and auditory cueing in a laboratory setting with a custom-made application for the Google Glass. Twelve participants (mean age = 66.8; mean disease duration = 13.6 years) were tested at end of dose. We compared several key gait parameters (walking speed, cadence, stride length, and stride length variability) and freezing of gait for three types of external cues (metronome, flashing light, and optic flow) and a control condition (no-cue). For all cueing conditions, the subjects completed several walking tasks of varying complexity. Seven inertial sensors attached to the feet, legs and pelvis captured motion data for gait analysis. Two experienced raters scored the presence and severity of freezing of gait using video recordings. User experience was evaluated through a semi-open interview. During cueing, a more stable gait pattern emerged, particularly on complicated walking courses; however, freezing of gait did not significantly decrease. The metronome was more effective than rhythmic visual cues and most preferred by the participants. Participants were overall positive about the usability of the Google Glass and willing to use it at home. Thus, smartglasses like the Google Glass could be used to provide personalized mobile cueing to support gait; however, in its current form, auditory cues seemed more effective than rhythmic visual cues.Entities:
Keywords: Assistive devices; External cueing; Freezing of gait; Gait; Smartglasses
Mesh:
Year: 2016 PMID: 27113598 PMCID: PMC4893372 DOI: 10.1007/s00415-016-8115-2
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849
Clinical characteristics of the subjects (N = 12) including scores for the Unified Parkinson’s disease rating scale Part III (UPDRS III, score/132), Hoehn and Yahr (score/5), New Freezing of Gait Questionnaire (N-FOGQ, score/33), Frontal Assessment Battery (FAB, score/18) and daily levodopa dosage
| Mean ± standard deviation | Range | |
|---|---|---|
| Age | 66.8 ± 6.8 | 53–78 |
| Gender |
| |
| Disease duration (years) | 13.6 ± 6.7 | 6–24 |
| UPDRS-part III | 35.2 ± 10.6 | 17–54 |
| HY-stage | 2 ( | 2–3 |
| N-FOGQ | 22.1 ± 5.1 | 13–31 |
| FAB | 15.7 ± 2.2 | 11–18 |
| Daily levodopa dosage (mg) | 809.1 ± 320.0 | 200–1200 |
Higher scores for the UPDRS, HY and N-FOGQ reflect worsening disability while low scores for FAB correspond to poorer performance
Other medications taken on the day of testing (daily dosage in mean ± standard deviation) included symmetrel (233.3 ± 115.5 mg, N = 3), rotigotine patch (8.0 ± 2.8 mg, N = 2), parlodel (15 ± 0.0 mg, N = 2), ropinirole (16 ± 5.7 mg, N = 2), elderpryl (10 mg, N = 1), comtan (600 mg, N = 1), rivastigmine (6 mg, N = 1), fluvoxamine (50 mg, N = 1), pramipexole teva (1.05 mg, N = 1), entacapone (800 mg, N = 1), tamsulosin (0.4 mg, N = 1), clopidogrel (75 mg, N = 1), oxazepam (20 mg, N = 1), macrogol (10 mg, N = 1), simvastatin (20 mg, N = 1), metoprolol (50 mg, N = 1), aspirin (80 mg, N = 1), allopurinol (100 mg, N = 1), omeprazole (20 mg, N = 1), and carbasalate calcium (100 mg, N = 1)
Fig. 1a A transparent prism mounted on the top right of the frame of the Google Glass displayed visual cues such as optical flow. b Flow diagram of the cueing app: The app was voice activated using the prompt “OK glass” followed by choosing “Start coaching” from the list of possible actions. From the main menu of the “PD App,” users could scroll, tap, or swipe to select a desired cueing frequency and choose the type of cue to provide. The app could be stopped at any time. c Walking courses: i–iv 10 m walk forward and back with a i wide or ii, iii narrow U-turn and a iii full 360° turn halfway back. iv 2 m walk with a right turn through a doorway and turning 180° to walk back
Fig. 2Typical a acceleration and b velocity waveforms recorded at the feet in the anterior–posterior orientation during a walking trial. The colored bars below the waveforms indicate the type of activity performed at each time point, including walking forward towards the midpoint, turning 180°, walking back the to starting positions, and FOG
Number of patients (N = 12) who exhibited FOG for different combinations of cueing conditions and specific movements
| 90° Turn | Narrow 180° turn | 360° Turn | |
|---|---|---|---|
| None | 0 | 1 | 7 |
| Metronome | 0 | 2 | 5 |
| Optic flow | 0 | 2 | 3 |
| LED | 1 | 3 | 3 |
No FOG was detected during forward walking and wide 180° turns. 90° turns were only performed during the doorway course. Narrow 180° turns were present in the narrow turn, full turn, and doorway courses. 360° turns only occurred during the full turn course
Fig. 3Effect of cueing on FOG and gait. a–d Box-whisker plots of the number of FOG episodes per trial (a, b) and their duration (c, d) for each type of turn (a, c) and cueing condition (b, d) (N = 12). e–j The stride length (e) and its standard deviation (SD) (f), speed (g), cadence (h), and deviation of the cadence from the cueing frequency (i, j) for different combinations of cues and walking courses in mean ± standard error (e–i) or as a box-whisker plot (j) (N = 11)